Ratings by Morgan Stanley (Matthew Harrison)
Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
4/24/2024 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
4/9/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
4/9/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
4/9/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
4/9/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
4/8/2024 | Adagene Inc | ADAG | Maintain | Overweight (N/A) |
|
Details | ||
3/19/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Equalweight (Overweight) |
10.64 (21.40) |
101.13% | Details | |
3/13/2024 | Regeneron Pharma | REGN | Maintain | (N/A) |
|
Details | ||
3/13/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
3/13/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
2/23/2024 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
2/20/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
2/14/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
2/8/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
2/5/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
12/22/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
11/29/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
11/28/2023 | argenx SE | ARGX | Maintain | Overweight () |
|
Details | ||
11/15/2023 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
11/10/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
11/8/2023 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
11/8/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
11/6/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
11/6/2023 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
11/3/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
11/2/2023 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
11/1/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
10/31/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
10/27/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
10/26/2023 | Centessa Pharmaceuticals | CNTA | Upgrade | Equalweight (Underweight) |
6.64 (9.46) |
42.47% | Details | |
10/17/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
10/11/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
10/11/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
10/9/2023 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
9/5/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
8/29/2023 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
8/18/2023 | Vaccitech | VACC | Maintain | Overweight (N/A) |
|
Details | ||
8/15/2023 | IO Biotech | IOBT | Maintain | Overweight (N/A) |
|
Details | ||
8/10/2023 | Tenaya Therapeutics Inc | TNYA | Maintain | Overweight (N/A) |
|
Details | ||
8/8/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
8/7/2023 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
8/4/2023 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
8/4/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
8/4/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
8/3/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
8/3/2023 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
8/2/2023 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
7/28/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
7/28/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
7/26/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
7/20/2023 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
7/20/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
7/20/2023 | 2Seventy Bio Inc. | TSVT | Maintain | Overweight (N/A) |
|
Details | ||
7/12/2023 | ADC Therapeutics | ADCT | Maintain | Equalweight (N/A) |
|
Details | ||
7/11/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
7/11/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
7/11/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
7/11/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
7/3/2023 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
7/3/2023 | Sigilon Therapeutics | SGTX | Maintain | Equalweight (N/A) |
|
Details | ||
5/26/2023 | Sigilon Therapeutics | SGTX | Maintain | Equalweight (N/A) |
|
Details | ||
5/16/2023 | Vaccitech | VACC | Maintain | Overweight (N/A) |
|
Details | ||
5/9/2023 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
5/9/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
5/8/2023 | Artivion Inc. | AORT | Maintain | Equalweight (N/A) |
|
Details | ||
5/5/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
5/5/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
5/5/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
5/1/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
4/28/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
4/25/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
4/14/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
4/12/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
4/12/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
4/12/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2023 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
4/12/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
4/3/2023 | bluebird bio | BLUE | Maintain | Underweight (N/A) |
|
Details | ||
3/30/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
3/28/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
3/27/2023 | Vigil Neuroscience Inc | VIGL | Maintain | Equalweight (N/A) |
|
Details | ||
3/17/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
3/15/2023 | Seagen | SGEN | Downgrade | Equalweight (Overweight) |
197.65 (228.74) |
15.73% | Details | |
3/10/2023 | Fulcrum Therapeutics | FULC | Maintain | Equalweight (N/A) |
|
Details | ||
3/3/2023 | Inova Technology, Inc. | INVA | Maintain | Underweight (N/A) |
|
Details | ||
3/3/2023 | Alector Inc. | ALEC | Maintain | Equalweight (N/A) |
|
Details | ||
3/1/2023 | Genmab A/S | GMAB | Maintain | Underweight (N/A) |
|
Details | ||
3/1/2023 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
3/1/2023 | Sarepta Therapeutics | SRPT | Upgrade | Overweight (Equalweight) |
118.13 (124.25) |
5.18% | Details | |
2/28/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
2/28/2023 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
2/28/2023 | Fulcrum Therapeutics | FULC | Downgrade | Equalweight (Overweight) |
5.66 (7.28) |
28.62% | Details | |
2/27/2023 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
2/24/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
2/23/2023 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
2/16/2023 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
1/27/2023 | Fusion Pharmaceuticals | FUSN | Maintain | Overweight (N/A) |
|
Details | ||
1/27/2023 | Taysha Gene Therapies | TSHA | Downgrade | Equalweight (Overweight) |
1.89 (2.35) |
24.34% | Details | |
1/5/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
1/5/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
12/19/2022 | bluebird bio | BLUE | Maintain | Underweight (N/A) |
|
Details | ||
11/18/2022 | Editas Medicine | EDIT | Maintain | Underweight (N/A) |
|
Details | ||
11/14/2022 | Prime Medicine | PRME | New Coverage | Equalweight (N/A) |
21.12 (4.70) |
-77.75% | Details | |
11/14/2022 | Lyell Immunopharma | LYEL | Downgrade | Equalweight (Overweight) |
4.96 (2.30) |
-53.63% | Details | |
11/4/2022 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
11/3/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
10/27/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
10/27/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
10/18/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
10/13/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
10/13/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
10/13/2022 | Legand Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
10/13/2022 | Inova Technology, Inc. | INVA | Maintain | Underweight (N/A) |
|
Details | ||
10/13/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
10/13/2022 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
10/13/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
10/13/2022 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
10/13/2022 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
10/12/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
10/11/2022 | Artivion Inc. | AORT | Maintain | Equalweight (N/A) |
|
Details | ||
10/11/2022 | Amgen | AMGN | Upgrade | Overweight (Equalweight) |
232.15 (273.01) |
17.6% | Details | |
9/27/2022 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
9/9/2022 | Adagene Inc | ADAG | Maintain | Overweight (N/A) |
|
Details | ||
9/9/2022 | Galapagos NV | GLPG | Downgrade | Equalweight (Overweight) |
48.24 (28.77) |
-40.36% | Details | |
9/9/2022 | Alector Inc. | ALEC | Downgrade | Equalweight (Overweight) |
10.72 (5.25) |
-51.03% | Details | |
9/9/2022 | ADC Therapeutics | ADCT | Downgrade | Equalweight (Overweight) |
6.16 (4.78) |
-22.4% | Details | |
9/9/2022 | Regeneron Pharma | REGN | Upgrade | Overweight (Equalweight) |
596.44 (906.54) |
51.99% | Details | |
9/8/2022 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
9/6/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
8/23/2022 | Pharvaris B.V. | PHVS | Downgrade | Equalweight (Overweight) |
18.49 (21.25) |
14.93% | Details | |
8/22/2022 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
8/12/2022 | Centessa Pharmaceuticals | CNTA | Downgrade | Underweight (Overweight) |
4.75 (9.46) |
99.16% | Details | |
8/8/2022 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
8/8/2022 | Inova Technology, Inc. | INVA | Maintain | Underweight (N/A) |
|
Details | ||
8/8/2022 | Artivion Inc. | AORT | Maintain | Equalweight (N/A) |
|
Details | ||
8/8/2022 | Alector Inc. | ALEC | Maintain | Overweight (N/A) |
|
Details | ||
8/8/2022 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
8/4/2022 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
8/4/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
8/3/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
7/26/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
7/5/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
6/23/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
6/22/2022 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
6/21/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
6/6/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
6/2/2022 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
5/24/2022 | Centessa Pharmaceuticals | CNTA | Maintain | Overweight (N/A) |
|
Details | ||
5/18/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
5/9/2022 | ADC Therapeutics | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
5/9/2022 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
5/9/2022 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
5/9/2022 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
5/9/2022 | Editas Medicine | EDIT | Maintain | Underweight (N/A) |
|
Details | ||
5/4/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
5/3/2022 | Vertex | VRTX | Upgrade | Equalweight (Underweight) |
273.22 (400.76) |
46.68% | Details | |
5/3/2022 | argenx SE | ARGX | Upgrade | Overweight (Equalweight) |
287.32 (375.00) |
30.52% | Details | |
5/2/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
5/2/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
4/28/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
4/26/2022 | argenx SE | ARGX | Maintain | Equalweight (N/A) |
|
Details | ||
4/25/2022 | Alnylam Pharmaceuticals | ALNY | Downgrade | Equalweight (Overweight) |
168.75 (143.80) |
-14.79% | Details | |
4/25/2022 | BioMarin Pharmaceutical Inc. | BMRN | Upgrade | Overweight (Equalweight) |
80.50 (91.20) |
13.29% | Details | |
4/18/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
4/12/2022 | Vertex | VRTX | Maintain | Underweight (N/A) |
|
Details | ||
4/12/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
4/12/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2022 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2022 | Kodiak Sciences Inc. | KOD | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2022 | Inova Technology, Inc. | INVA | Maintain | Underweight (N/A) |
|
Details | ||
4/12/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2022 | Fulcrum Therapeutics | FULC | Maintain | Overweight (N/A) |
|
Details | ||
4/12/2022 | Editas Medicine | EDIT | Maintain | Underweight (N/A) |
|
Details | ||
4/12/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2022 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
4/12/2022 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2022 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
4/12/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
4/12/2022 | ADC Therapeutics | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
4/6/2022 | Royalty Pharma | RPRX | Upgrade | Overweight (Equalweight) |
39.74 (27.98) |
-29.59% | Details | |
4/6/2022 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
4/6/2022 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
4/6/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
4/6/2022 | Bristol-Myers Squibb Co. | BMY | Downgrade | Underweight (Equalweight) |
73.79 (48.86) |
-33.79% | Details | |
4/6/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
4/5/2022 | Centessa Pharmaceuticals | CNTA | Maintain | Overweight (N/A) |
|
Details | ||
3/29/2022 | Vaccitech | VACC | Maintain | Overweight (N/A) |
|
Details | ||
3/29/2022 | 2Seventy Bio Inc. | TSVT | Maintain | Overweight (N/A) |
|
Details | ||
3/25/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
3/22/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
3/15/2022 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
3/10/2022 | Vertex | VRTX | Maintain | Underweight (N/A) |
|
Details | ||
3/7/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
3/7/2022 | Legand Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
3/7/2022 | bluebird bio | BLUE | Maintain | Underweight (N/A) |
|
Details | ||
3/7/2022 | argenx SE | ARGX | Maintain | Equalweight (N/A) |
|
Details | ||
2/25/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
2/24/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
2/24/2022 | Kodiak Sciences Inc. | KOD | Maintain | Equalweight (N/A) |
|
Details | ||
2/18/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Equalweight (N/A) |
|
Details | ||
2/15/2022 | argenx SE | ARGX | Maintain | Equalweight (N/A) |
|
Details | ||
2/10/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
2/10/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
2/9/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
2/2/2022 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
2/1/2022 | Vigil Neuroscience Inc | VIGL | New Coverage | Equalweight (N/A) |
14.65 (2.77) |
-81.09% | Details | |
1/31/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
1/31/2022 | Seagen | SGEN | Upgrade | Overweight (Equalweight) |
122.91 (228.74) |
86.1% | Details | |
1/31/2022 | Legand Biotech Corp. | LEGN | Upgrade | Overweight (Equalweight) |
35.78 (45.17) |
26.24% | Details | |
1/27/2022 | Vertex | VRTX | Maintain | Underweight (N/A) |
|
Details | ||
1/24/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
1/24/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
1/19/2022 | bluebird bio | BLUE | Maintain | Underweight (N/A) |
|
Details | ||
1/12/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
1/11/2022 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
1/11/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
1/6/2022 | Atea Pharmaceuticals | AVIR | Downgrade | Underweight (Equalweight) |
8.30 (3.70) |
-55.42% | Details | |
1/6/2022 | Adagio | ADGI | Downgrade | Underweight (Equalweight) |
6.50 (4.64) |
-28.62% | Details | |
1/6/2022 | Bolt Biotherapeutics, Inc. | BOLT | Downgrade | Equalweight (Overweight) |
4.20 (1.20) |
-71.43% | Details | |
1/6/2022 | Legand Biotech Corp. | LEGN | Downgrade | Equalweight (Overweight) |
46.75 (45.17) |
-3.38% | Details | |
1/6/2022 | Gilead Sciences | GILD | Downgrade | Equalweight (Overweight) |
72.21 (67.08) |
-7.1% | Details | |
12/16/2021 | BioNTech | BNTX | New Coverage | Equalweight (N/A) |
276.77 (88.09) |
-68.17% | Details | |
12/14/2021 | Adagio | ADGI | Downgrade | Equalweight (Overweight) |
34.26 (4.64) |
-86.46% | Details | |
11/30/2021 | IO Biotech | IOBT | New Coverage | Overweight (N/A) |
7.61 (1.46) |
-80.81% | Details | |
11/30/2021 | Sigilon Therapeutics | SGTX | Maintain | Equalweight (N/A) |
|
Details | ||
11/29/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
11/29/2021 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
11/29/2021 | Adagio | ADGI | Upgrade | Overweight (Equalweight) |
18.73 (34.26) |
82.92% | Details | |
11/23/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
11/22/2021 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Equalweight (N/A) |
|
Details | ||
11/17/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
11/8/2021 | 2Seventy Bio Inc. | TSVT | New Coverage | Overweight (N/A) |
33.62 (4.27) |
-87.3% | Details | |
11/8/2021 | bluebird bio | BLUE | Downgrade | Underweight (Equalweight) |
13.14 (0.92) |
-93% | Details | |
11/8/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
11/8/2021 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
11/5/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
11/5/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
11/2/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
11/1/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
10/29/2021 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
10/29/2021 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
10/21/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
10/20/2021 | Atea Pharmaceuticals | AVIR | Maintain | Equalweight (N/A) |
|
Details | ||
10/19/2021 | Freeline | FRLN | Maintain | Overweight (N/A) |
|
Details | ||
10/19/2021 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
10/19/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
10/12/2021 | Vertex | VRTX | Maintain | Underweight (N/A) |
|
Details | ||
10/12/2021 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
10/12/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
10/12/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
10/12/2021 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
10/12/2021 | Legand Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
10/12/2021 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
10/12/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
10/12/2021 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
10/12/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
10/12/2021 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
10/8/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
10/5/2021 | Atea Pharmaceuticals | AVIR | Downgrade | Equalweight (Overweight) |
42.01 (3.70) |
-91.19% | Details | |
9/14/2021 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
9/7/2021 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
9/7/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
9/7/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
9/7/2021 | argenx SE | ARGX | Downgrade | Equalweight (Overweight) |
349.07 (375.00) |
7.43% | Details | |
9/7/2021 | Vertex | VRTX | Downgrade | Underweight (Equalweight) |
199.22 (400.76) |
101.16% | Details | |
9/7/2021 | Merck | MRK | Downgrade | Equalweight (Overweight) |
77.12 (127.00) |
64.68% | Details | |
9/7/2021 | Johnson & Johnson | JNJ | Downgrade | Equalweight (Overweight) |
174.93 (148.53) |
-15.09% | Details | |
9/7/2021 | Genmab A/S | GMAB | Downgrade | Underweight (Equalweight) |
48.71 (28.47) |
-41.55% | Details | |
9/7/2021 | Amgen | AMGN | Downgrade | Equalweight (Overweight) |
225.96 (232.15) |
2.74% | Details | |
8/31/2021 | Adagio | ADGI | New Coverage | Equalweight (N/A) |
30.38 (4.64) |
-84.73% | Details | |
8/27/2021 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
8/24/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
8/24/2021 | Tenaya Therapeutics Inc | TNYA | New Coverage | Overweight (N/A) |
22.67 (4.38) |
-80.68% | Details | |
8/20/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
8/18/2021 | Taysha Gene Therapies | TSHA | Maintain | Overweight (N/A) |
|
Details | ||
8/18/2021 | Fusion Pharmaceuticals | FUSN | Maintain | Overweight (N/A) |
|
Details | ||
8/18/2021 | Atea Pharmaceuticals | AVIR | Maintain | Overweight (N/A) |
|
Details | ||
8/18/2021 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
8/16/2021 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
8/16/2021 | Royalty Pharma | RPRX | Maintain | Equalweight (N/A) |
|
Details | ||
8/16/2021 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
8/16/2021 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
8/16/2021 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
8/11/2021 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
8/11/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
8/11/2021 | Imara Inc. | IMRA | Downgrade | Equalweight (Overweight) |
5.90 (6.32) |
7.12% | Details | |
8/11/2021 | Fulcrum Therapeutics | FULC | Upgrade | Overweight (Equalweight) |
8.33 (7.28) |
-12.61% | Details | |
7/29/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
7/29/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
7/23/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
7/16/2021 | Sigilon Therapeutics | SGTX | Maintain | Equalweight (N/A) |
|
Details | ||
7/16/2021 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
7/16/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
7/16/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
7/16/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
7/16/2021 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
7/16/2021 | Alector Inc. | ALEC | Maintain | Overweight (N/A) |
|
Details | ||
7/16/2021 | Adagene Inc | ADAG | Maintain | Overweight (N/A) |
|
Details | ||
7/16/2021 | ADC Therapeutics | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
7/12/2021 | Lyell Immunopharma | LYEL | New Coverage | Overweight (N/A) |
15.25 (2.30) |
-84.92% | Details | |
6/22/2021 | Centessa Pharmaceuticals | CNTA | New Coverage | Overweight (N/A) |
24.91 (9.46) |
-62.02% | Details | |
6/18/2021 | Cerevel Therapeutics | CERE | New Coverage | Overweight (N/A) |
13.49 (41.90) |
210.6% | Details | |
6/11/2021 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
6/10/2021 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
6/8/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
6/3/2021 | BeiGene, Ltd. | BGNE | Maintain | Overweight (Overweight) |
|
Details | ||
6/3/2021 | Atea Pharmaceuticals | AVIR | Maintain | Overweight (Overweight) |
|
Details | ||
5/25/2021 | Vaccitech | VACC | New Coverage | Overweight (N/A) |
14.58 (5.00) |
-65.71% | Details | |
5/18/2021 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
5/18/2021 | Fusion Pharmaceuticals | FUSN | Maintain | Overweight (Overweight) |
|
Details | ||
5/18/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (Equalweight) |
|
Details | ||
5/11/2021 | Galapagos NV | GLPG | Maintain | Overweight (Overweight) |
|
Details | ||
5/10/2021 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
5/10/2021 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
5/10/2021 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
5/10/2021 | Editas Medicine | EDIT | Maintain | Underweight (N/A) |
|
Details | ||
5/10/2021 | ADC Technologies | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
5/7/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
5/6/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
5/3/2021 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (Equalweight) |
|
Details | ||
4/30/2021 | Vertex | VRTX | Maintain | Equalweight (Equalweight) |
|
Details | ||
4/30/2021 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
4/28/2021 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
4/13/2021 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
4/6/2021 | Fusion Pharmaceuticals | FUSN | Maintain | Overweight (Overweight) |
|
Details | ||
4/6/2021 | Freeline | FRLN | Maintain | Overweight (Overweight) |
|
Details | ||
4/6/2021 | Atea Pharmaceuticals | AVIR | Maintain | Overweight (Overweight) |
|
Details | ||
3/29/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
3/26/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
3/22/2021 | Akero Therapeutics | AKRO | Maintain | Overweight (Overweight) |
|
Details | ||
3/22/2021 | ADC Technologies | ADCT | Maintain | Overweight (Overweight) |
|
Details | ||
3/11/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
3/11/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
3/11/2021 | Galapagos NV | GLPG | Maintain | Overweight (Overweight) |
|
Details | ||
3/8/2021 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
3/8/2021 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
3/8/2021 | Regenxbio Inc. | RGNX | Maintain | Overweight (Overweight) |
|
Details | ||
3/8/2021 | Kodiak Sciences Inc. | KOD | Maintain | Equalweight (Equalweight) |
|
Details | ||
3/8/2021 | Kaleido Biosciences Inc. | KLDO | Maintain | Equalweight (Equalweight) |
|
Details | ||
3/8/2021 | Imara Inc. | IMRA | Maintain | Overweight (Overweight) |
|
Details | ||
3/8/2021 | Fulcrum Therapeutics | FULC | Maintain | Equalweight (Equalweight) |
|
Details | ||
3/8/2021 | Adagene Inc | ADAG | New Coverage | Overweight (N/A) |
22.99 (2.75) |
-88.04% | Details | |
3/5/2021 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
3/2/2021 | Pharvaris B.V. | PHVS | New Coverage | Overweight (N/A) |
39.23 (21.25) |
-45.83% | Details | |
3/2/2021 | Sage Therapeutics | SAGE | Maintain | Equalweight (Equalweight) |
|
Details | ||
3/2/2021 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
3/2/2021 | Editas Medicine | EDIT | Maintain | Underweight (Underweight) |
|
Details | ||
3/2/2021 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Overweight (N/A) |
26.70 (1.20) |
-95.51% | Details | |
3/2/2021 | bluebird bio | BLUE | Maintain | Equalweight (Equalweight) |
|
Details | ||
2/26/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
2/25/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
2/24/2021 | Huntington Bancshares | HBAN | Maintain | Equalweight (Equalweight) |
|
Details | ||
2/18/2021 | Moderna | MRNA | Maintain | Equalweight (Equalweight) |
|
Details | ||
2/17/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
2/12/2021 | Seagen | SGEN | Maintain | Equalweight (Equalweight) |
|
Details | ||
2/8/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (Equalweight) |
|
Details | ||
2/5/2021 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
2/4/2021 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
2/3/2021 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
2/2/2021 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
1/26/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
1/21/2021 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
1/19/2021 | Galapagos NV | GLPG | Maintain | Overweight (Equalweight) |
|
Details | ||
1/19/2021 | BeiGene, Ltd. | BGNE | Maintain | Overweight (Overweight) |
|
Details | ||
1/19/2021 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
1/19/2021 | Vertex | VRTX | Maintain | Equalweight (Equalweight) |
|
Details | ||
1/19/2021 | Regenxbio Inc. | RGNX | Maintain | Overweight (Overweight) |
|
Details | ||
1/19/2021 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (Equalweight) |
|
Details | ||
1/19/2021 | Kaleido Biosciences Inc. | KLDO | Maintain | Equalweight (Equalweight) |
|
Details | ||
1/19/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (Equalweight) |
|
Details | ||
1/19/2021 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
1/19/2021 | Seagen | SGEN | Maintain | Equalweight (Equalweight) |
|
Details | ||
1/19/2021 | Genmab A/S | GMAB | Downgrade | Equalweight (Overweight) |
44.12 (28.47) |
-35.47% | Details | |
1/19/2021 | Gilead Sciences | GILD | Upgrade | Overweight (Equalweight) |
62.40 (67.08) |
7.5% | Details | |
1/19/2021 | Silicon Labs | SLAB | New Coverage | Equalweight (N/A) |
135.45 (114.26) |
-15.64% | Details | |
1/19/2021 | Editas Medicine | EDIT | Downgrade | Underweight (Equalweight) |
75.92 (5.35) |
-92.95% | Details | |
1/8/2021 | Sarepta Therapeutics | SRPT | Downgrade | Equalweight (Overweight) |
166.45 (124.25) |
-25.35% | Details | |
12/30/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
12/29/2020 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
12/29/2020 | Sigilon Therapeutics | SGTX | New Coverage | Equalweight (N/A) |
41.20 (22.47) |
-45.46% | Details | |
12/24/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
12/16/2020 | Moderna | MRNA | Downgrade | Equalweight (Overweight) |
155.07 (108.85) |
-29.81% | Details | |
12/11/2020 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
12/4/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
12/1/2020 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
11/16/2020 | Sage Therapeutics | SAGE | Downgrade | Equalweight (Overweight) |
78.00 (44.07) |
-43.5% | Details | |
11/16/2020 | Kodiak Sciences Inc. | KOD | Downgrade | Equalweight (Overweight) |
122.63 (3.38) |
-97.24% | Details | |
11/12/2020 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
11/11/2020 | Zentalis Pharmaceuticals | ZNTL | Maintain | Overweight (N/A) |
|
Details | ||
11/11/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
11/11/2020 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
11/11/2020 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
11/11/2020 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
11/11/2020 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
11/11/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
11/11/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
11/3/2020 | Gilead Sciences | GILD | New Coverage | Equalweight (N/A) |
58.15 (67.08) |
15.36% | Details | |
10/22/2020 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
8/24/2020 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
8/24/2020 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
8/24/2020 | Zentalis Pharmaceuticals | ZNTL | Maintain | Overweight (N/A) |
|
Details | ||
8/24/2020 | Allovir Inc. | ALVR | New Coverage | Overweight (N/A) |
30.85 (20.92) |
-32.19% | Details | |
8/21/2020 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
8/21/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Equalweight (N/A) |
|
Details | ||
8/12/2020 | Fulcrrum Therapeutics | FULC | Downgrade | Equalweight (Overweight) |
17.12 (7.28) |
-57.48% | Details | |
8/10/2020 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
8/10/2020 | Kaleido Biosciences Inc. | KLDO | Maintain | Equalweight (N/A) |
|
Details | ||
8/10/2020 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
8/10/2020 | Immunomedics | IMMU | Maintain | Equalweight (N/A) |
|
Details | ||
8/10/2020 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
8/10/2020 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
8/10/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
8/10/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
8/6/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
8/6/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
7/31/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
7/29/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
7/27/2020 | Biogen | BIIB | Upgrade | Overweight (Equalweight) |
278.51 (201.99) |
-27.47% | Details | |
7/15/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
7/15/2020 | Kaleido Biosciences Inc. | KLDO | Maintain | Equalweight (N/A) |
|
Details | ||
7/15/2020 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
7/15/2020 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
7/15/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
7/15/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
7/15/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
7/15/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
7/9/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
7/8/2020 | BioMarin Pharmaceutical Inc. | BMRN | Downgrade | Equalweight (Overweight) |
127.71 (91.20) |
-28.59% | Details | |
7/8/2020 | Vertex | VRTX | Downgrade | Equalweight (Overweight) |
291.31 (400.76) |
37.57% | Details | |
6/30/2020 | Legend Biotech Corp. | LEGN | New Coverage | Overweight (N/A) |
40.03 (45.17) |
12.84% | Details | |
5/28/2020 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
5/28/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
5/28/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
5/27/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
5/21/2020 | Kaleido Biosciences Inc. | KLDO | Downgrade | Equalweight (Overweight) |
6.45 (0.29) |
-95.5% | Details | |
5/21/2020 | Evelo Biosciences Inc | EVLO | Downgrade | Equalweight (Overweight) |
4.32 (0.32) |
-92.59% | Details | |
5/20/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
5/7/2020 | Immunomedics | IMMU | Maintain | Equalweight (N/A) |
|
Details | ||
5/7/2020 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
5/7/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Equalweight (N/A) |
|
Details | ||
5/6/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
5/4/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
5/1/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
4/28/2020 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Overweight (N/A) |
30.50 (11.77) |
-61.41% | Details | |
4/23/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
4/7/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
3/3/2020 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
3/3/2020 | Immunomedics | IMMU | Maintain | Equalweight (N/A) |
|
Details | ||
3/3/2020 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
3/3/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
3/3/2020 | Forty Seven Inc. | FTSV | Downgrade | Equalweight (Overweight) |
58.00 (95.51) |
64.67% | Details | |
2/26/2020 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
2/26/2020 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
2/18/2020 | Evelo Biosciences Inc | EVLO | Maintain | Overweight (N/A) |
|
Details | ||
2/7/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
2/7/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
2/6/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
2/4/2020 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
1/31/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
1/31/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Equalweight (N/A) |
|
Details | ||
1/17/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
1/17/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
1/17/2020 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
1/17/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
1/17/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
1/17/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
1/17/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Equalweight (N/A) |
|
Details | ||
1/17/2020 | BeiGene, Ltd. | BGNE | New Coverage | Overweight (N/A) |
167.85 (144.12) |
-14.14% | Details | |
12/24/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
12/17/2019 | Kodiak Sciences Inc. | KOD | Maintain | Overweight (N/A) |
|
Details | ||
12/17/2019 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
12/17/2019 | Amgen | AMGN | New Coverage | Overweight (N/A) |
243.20 (273.01) |
12.26% | Details | |
12/17/2019 | Alexion Pharmaceuticals | ALXN | Downgrade | Equalweight (Overweight) |
110.42 (182.01) |
64.83% | Details | |
12/10/2019 | Forty Seven Inc. | FTSV | Maintain | Overweight (N/A) |
|
Details | ||
12/10/2019 | Seattle Genetics | SGEN | New Coverage | Equalweight (N/A) |
117.50 (228.74) |
94.67% | Details | |
12/6/2019 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
11/19/2019 | Cabaletta Bio Inc. | CABA | New Coverage | Overweight (N/A) |
14.00 (12.74) |
-9% | Details | |
11/11/2019 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
11/11/2019 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
11/6/2019 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
11/5/2019 | Kodiak Sciences Inc. | KOD | Maintain | Overweight (N/A) |
|
Details | ||
11/1/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
11/1/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
11/1/2019 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
10/29/2019 | Galapagos NV | GLPG | Maintain | Overweight (N/A) |
|
Details | ||
10/28/2019 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
10/28/2019 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
10/23/2019 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
10/11/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2019 | Forty Seven Inc. | FTSV | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2019 | Evelo Biosciences Inc | EVLO | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
10/11/2019 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
10/11/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
9/9/2019 | Galapagos NV | GLPG | New Coverage | Overweight (N/A) |
162.04 (28.77) |
-82.25% | Details | |
9/6/2019 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
9/5/2019 | Incyte | INCY | New Coverage | Equalweight (N/A) |
80.06 (51.74) |
-35.37% | Details | |
8/12/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
8/9/2019 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
8/9/2019 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
8/9/2019 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
8/9/2019 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
8/9/2019 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
8/6/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
8/6/2019 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
8/6/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
8/6/2019 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
7/17/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
7/15/2019 | Unum Therapeutics | UMRX | Maintain | Overweight (N/A) |
|
Details | ||
7/15/2019 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
7/15/2019 | Forty Seven Inc. | FTSV | Maintain | Overweight (N/A) |
|
Details | ||
7/15/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
7/15/2019 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
7/9/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
6/5/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
5/28/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
5/21/2019 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
5/8/2019 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
5/1/2019 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
4/29/2019 | Galapagos NV | GLPG | Maintain | Overweight (N/A) |
|
Details | ||
4/26/2019 | Alexion Pharmaceuticals | ALXn | Maintain | Overweight (N/A) |
|
Details | ||
4/9/2019 | Biohaven Pharmaceutical Holding | BHVN | Downgrade | Equalweight (Overweight) |
50.19 (38.72) |
-22.85% | Details | |
3/4/2019 | Portola Pharmaceuticals | PTLA | Maintain | Overweight (N/A) |
|
Details | ||
3/4/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
3/4/2019 | MacroGenics | MGNX | Maintain | Overweight (N/A) |
|
Details | ||
3/4/2019 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details | ||
3/4/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
2/26/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
2/25/2019 | Galapagos NV | GLPG | Maintain | Overweight (N/A) |
|
Details | ||
2/25/2019 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
2/25/2019 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
2/12/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
2/8/2019 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
1/30/2019 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
1/30/2019 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
1/22/2019 | Immunomedics | IMMU | Downgrade | Equalweight (Overweight) |
13.31 (87.86) |
560.11% | Details | |
1/4/2019 | argenx SE | ARGX | New Coverage | Overweight (N/A) |
98.85 (375.00) |
279.36% | Details | |
1/2/2019 | Moderna | MRNA | New Coverage | Overweight (N/A) |
15.27 (108.85) |
612.84% | Details | |
12/20/2018 | DBV Technologies S.A | DBVT | Maintain | Equalweight (N/A) |
|
Details | ||
11/7/2018 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
11/5/2018 | Galapagos NV | GLPG | Maintain | Overweight (N/A) |
|
Details | ||
11/5/2018 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
11/5/2018 | Immunomedics | IMMU | New Coverage | Overweight (N/A) |
24.03 (13.31) |
-44.61% | Details | |
11/2/2018 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
10/31/2018 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
10/29/2018 | Kodiak Sciences Inc. | KOD | New Coverage | Overweight (N/A) |
9.56 (3.38) |
-64.64% | Details | |
10/26/2018 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
10/24/2018 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Unum Therapeutics | UMRX | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
10/11/2018 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
10/11/2018 | Loxo Oncology | LOXO | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
10/11/2018 | Forty Seven Inc. | FTSV | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Evelo Biosciences Inc | EVLO | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
10/11/2018 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
9/11/2018 | DBV Technologies S.A | DBVT | Maintain | Equalweight (N/A) |
|
Details | ||
9/10/2018 | Voyager Therapeutics | VYGR | New Coverage | Equalweight (Overweight) |
19.56 (7.57) |
-61.3% | Details | |
8/13/2018 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
8/13/2018 | Rubius | RUBY | New Coverage | Overweight (N/A) |
21.93 (0.08) |
-99.64% | Details |